---
title: Improve walking and leg function
nct_id: NCT06690931
phase: NA
status: RECRUITING
sponsor: g.tec medical engineering GmbH
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06690931"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06690931"
last_fetched: "2026-05-10T14:07:14.645Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking and leg function

**Goal (in five words):** Improve walking and leg function

**Official Title:** Parkinson's Disease Rehabilitation Using Neurofeedback With Functional Electrical Stimulation and Virtual Reality Feedback for Lower Extremities

**Trial ID:** [NCT06690931](https://clinicaltrials.gov/study/NCT06690931)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** g.tec medical engineering GmbH
- **Target Enrollment:** 30 participants
- **Start Date:** 2024-12-09
- **Completion Date:** 2027-08
- **Conditions:** Parkinson Disease
- **Interventions:** Brain-Computer Interface with FES and VR, Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback
- **Intervention Types:** DEVICE

## Summary For Families

The trial aims to improve walking, balance, and lower limb function in people with Parkinson's by retraining the brain-to-muscle connection that helps you move more smoothly. It uses a brain-computer interface to detect imagined leg movements, triggers small electrical pulses to the leg muscles with functional electrical stimulation, and gives real-time virtual reality feedback so your brain practices the intended movement while the muscles actually activate. The program is a rehabilitation approach used while you stay on your usual, stable Parkinson's medications, not a drug treatment; it cannot be used by people with implanted devices like pacemakers or metal fragments that make FES unsafe. They're enrolling people aged 40 to 80 with Parkinson's at Hoehn and Yahr stages 1 to 3 who can walk independently, have stable meds and neurological status, and do not have major comorbidities, severe depression, uncontrolled diabetes, unpredictable motor fluctuations, pregnancy, or other barriers to using a BCI or FES.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of PD
* HY stage between 1 to 3
* Age between 40 - 80 years old
* Ability to walk independently
* Stable medication usage
* Stable neurological condition
* Able to sign the informed consent.
* Able to follow the study protocol.

Exclusion Criteria:

* Other neurological diseases
* Severe depression
* Uncontrolled diabetes
* Concomitant severe neurologic, cardiopulmonary, or orthopedic disorders
* Debilitating conditions or vision impairment that would impede full participation in the study.
* Unpredictable motor fluctuations
* Pregnant
* Active or passive implanted medical devices such as pacemakers which do not allow the use of FES.
* Implanted metallic fragments in the upper and lower extremities which can limit the use of FES.
* Under the influence of anesthesia or similar medication.
* With fractures or lesions in the upper and lower extremities.
* Inadequate control of a BCI system.
```

## Locations (1)

- g.tec medical engineering GmbH, Schiedlberg, Upper Austria, Austria _(48.0911, 14.2635)_
  - Christoph Guger, PhD — (CONTACT) — +43725122240 — guger@gtec.at
  - Rupert Ortner, PhD — (CONTACT) — +43725122240 — ortner@gtec.at
  - Michael Guger, MD — (PRINCIPAL_INVESTIGATOR)
  - Christoph Guger, PhD — (SUB_INVESTIGATOR)
  - Rupert Ortner, PhD — (SUB_INVESTIGATOR)
  - Marc Sebastián-Romagosa, PhD — (SUB_INVESTIGATOR)
  - Woosang Cho, PhD — (SUB_INVESTIGATOR)
  - Sebastian Sieghartsleitner — (SUB_INVESTIGATOR)

## Central Contacts

- Rupert Ortner, PhD — (CONTACT) — +43725122240 — ortner@gtec.at
- Marc Sebastián-Romagosa, PhD — (CONTACT) — +34936764579 — sebastian@gtec.at

---

*Canonical: https://parkinsonspathways.com/trial/NCT06690931*  
*HTML version: https://parkinsonspathways.com/trial/NCT06690931*  
*Source data: https://clinicaltrials.gov/study/NCT06690931*